Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer

Cancer Research

Volumn 70, Issue 20, 2010, Pages 8025-8035

  Kohmo, Satoshi ^a   Kijima, Takashi ^a   Otani, Yasushi ^a   Mori, Masahide ^b   Minami, Toshiyuki ^a   Takahashi, Ryo ^a   Nagatomo, Izumi ^a   Takeda, Yoshito ^a   Kida, Hiroshi ^a   Goya, Sho ^a   Yoshida, Mitsuhiro ^a   Kumagai, Toru ^a,c   Tachibana, Isao ^a   Yokota, Soichiro ^b   Kawase, Ichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TONEYAMA NATIONAL HOSPITAL   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMRUBICIN; BETA1 INTEGRIN; CD9 ANTIGEN; CISPLATIN; ETOPOSIDE; FIBRONECTIN; TETRASPANIN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL ADHESION; DOWN REGULATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CARCINOMA, SMALL CELL; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL12; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICROSCOPY, VIDEO; NEOPLASM METASTASIS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SMALL CELL LUNG CARCINOMA;

EID: 78049316293     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0996     Document Type: Article

References (48)

1. Hanna NH, Einhorn LH. Small-cell lung cancer: state of the art. Clin Lung Cancer 2002;4:87-94.
2. Stupp R, Monnerat C, Turrisi AT 3rd, et al. Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004;45:105-17.
3. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-18.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
5. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
6. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31.
7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
8. Borst P, Schinkel AH, Smit JJ, et al. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 1993;60:289-99.
9. Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994;54:5902-10.
10. Canitrot Y, Bichat F, Cole SP, et al. Multidrug resistance genes (MRP) and MDR1 expression in small cell lung cancer xenografts: relationship with response to chemotherapy. Cancer Lett 1998;130:133-41.
11. Dingemans AM, Witlox MA, Stallaert RA, et al. Expression of DNA topoisomerase IIα and topoisomerase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 1999;5:2048-58.
12. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662-8.
13. Rintoul RC, Sethi T. The role of extracellular matrix in small-cell lung cancer. Lancet Oncol 2001;2:437-42.
14. Kraus AC, Ferber I, Bachmann SO, et al. In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002;21:8683-95.
15. Kijima T, Maulik G, Ma PC, et al. Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer. J Cell Mol Med 2003;7:157-64.
16. Tsurutani J, West KA, Sayyah J, et al. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 2005;65:8423-32.
17. Hodkinson PS, Elliott T, Wong WS, et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through β1 integrin-dependent activation of PI3-kinase. Cell Death Differ 2006;13:1776-88.
18. Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001;20:4995-5004.
19. Hazlehurst LA, Damiano JS, Buyuksal I, et al. Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000;19:4319-27.
20. Hazlehurst LA, Valkov N, Wisner L, et al. Reduction in drug-induced DNA double-strand breaks associated with β1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 2001;98:1897-903.
21. Kouniavsky G, Khaikin M, Zvibel I, et al. Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. Clin Exp Metastasis 2002;19:55-60.
22. Uhm JH, Dooley NP, Kyritsis AP, et al. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res 1999;5:1587-94.
23. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005;6:801-11.
24. Levy S, Shoham T. Protein-protein interactions in the tetraspanin web. Physiology (Bethesda) 2005;20:218-24.
25. Miyake M, Koyama M, Seno M, et al. Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J Exp Med 1991;174:1347-54.
26. Ikeyama S, Koyama M, Yamaoko M, et al. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 1993;177:1231-7.
27. Higashiyama M, Taki T, Ieki Y, et al. Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in nonsmall cell lung cancer. Cancer Res 1995;55:6040-4.
28. Higashiyama M, Doi O, Kodama K, et al. Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int J Cancer 1997;74:205-11.
29. Funakoshi T, Tachibana I, Hoshida Y, et al. Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer. Oncogene 2003;22:674-87.
30. Miyamoto H. Establishment and characterization of an adriamycin-resistant subline of human small cell lung cancer cells. Acta Med Okayama 1986;40:65-73. (Pubitemid 17173391)
31. Moritaka T, Kiura K, Ueoka H, et al. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids. Anticancer Res 1998;18:927-33.
32. Takigawa N, Ohnoshi T, Ueoka H, et al. Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. Acta Med Okayama 1992;46:203-12.
33. Hong WS, Saijo N, Sasaki Y, et al. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int J Cancer 1988;41:462-7.
34. Minato K, Kanzawa F, Nishio K, et al. Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother Pharmacol 1990;26:313-7.
35. Suzuki M, Tachibana I, Takeda Y, et al. Tetraspanin CD9 negatively regulates lipopolysaccharide-induced macrophage activation and lung inflammation. J Immunol 2009;182:6485-93.
36. Kijima T, Maulik G, Ma PC, et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 2002;62:6304-11.
37. Feldman LE, Shin KC, Natale RB, et al. β1 integrin expression on human small cell lung cancer cells. Cancer Res 1991;51:1065-70.
38. Buttery RC, Rintoul RC, Sethi T. Small cell lung cancer: the importance of the extracellular matrix. Int J Biochem Cell Biol 2004;36:1154-60.
39. Hodkinson PS, Mackinnon AC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol 2007;83:733-41.
40. Murayama Y, Miyagawa J, Oritani K, et al. CD9-mediated activation of the p46 Shc isoform leads to apoptosis in cancer cells. J Cell Sci 2004;117:3379-88.
41. Rintoul RC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Sci (Lond) 2002;102:417-24.
42. Nakamoto T, Murayama Y, Oritani K, et al. A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J Gastroenterol 2009;44:889-96.
43. Ovalle S, Gutierrez-Lopez MD, Olmo N, et al. The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells. Int J Cancer 2007;121:2140-52.
44. Klein-Soyer C, Azorsa DO, Cazenave JP, et al. CD9 participates in endothelial cell migration during in vitro wound repair. Arterioscler Thromb Vasc Biol 2000;20:360-9.
45. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
46. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007;13:1552-61.
47. Roda JM, Joshi T, Butchar JP, et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007;13:6419-28.
48. Sondermann P, Kaiser J, Jacob U. Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J Mol Biol 2001;309:737-49.